Cargando…

Overcoming the Low Oral Bioavailability of Deuterated Pyrazoloquinolinone Ligand DK-I-60-3 by Nanonization: A Knowledge-Based Approach

Poor water solubility of new chemical entities is considered as one of the main obstacles in drug development, as it usually leads to low bioavailability after administration. To overcome these problems, the selection of the appropriate formulation technology needs to be based on the physicochemical...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitrović, Jelena R., Divović-Matović, Branka, Knutson, Daniel E., Đoković, Jelena B., Kremenović, Aleksandar, Dobričić, Vladimir D., Randjelović, Danijela V., Pantelić, Ivana, Cook, James M., Savić, Miroslav M., Savić, Snežana D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400889/
https://www.ncbi.nlm.nih.gov/pubmed/34452149
http://dx.doi.org/10.3390/pharmaceutics13081188
_version_ 1783745420624658432
author Mitrović, Jelena R.
Divović-Matović, Branka
Knutson, Daniel E.
Đoković, Jelena B.
Kremenović, Aleksandar
Dobričić, Vladimir D.
Randjelović, Danijela V.
Pantelić, Ivana
Cook, James M.
Savić, Miroslav M.
Savić, Snežana D.
author_facet Mitrović, Jelena R.
Divović-Matović, Branka
Knutson, Daniel E.
Đoković, Jelena B.
Kremenović, Aleksandar
Dobričić, Vladimir D.
Randjelović, Danijela V.
Pantelić, Ivana
Cook, James M.
Savić, Miroslav M.
Savić, Snežana D.
author_sort Mitrović, Jelena R.
collection PubMed
description Poor water solubility of new chemical entities is considered as one of the main obstacles in drug development, as it usually leads to low bioavailability after administration. To overcome these problems, the selection of the appropriate formulation technology needs to be based on the physicochemical properties of the drug and introduced in the early stages of drug research. One example of the new potential drug substance with poor solubility is DK-I-60-3, deuterated pyrazoloquinolinone, designed for the treatment of various neuropsychiatric disorders. In this research, based on preformulation studies, nanocrystal technology was chosen to improve the oral bioavailability of DK-I-60-3. Nanocrystal dispersions stabilized by sodium lauryl sulfate and polyvinylpyrrolidone were prepared by modified wet media milling technique, with the selection of appropriate process and formulation parameters. The nanoparticles characterization included particle size and zeta potential measurements, differential scanning calorimetry, X-ray powder diffraction, dissolution and solubility study, and in vivo pharmacokinetic experiments. Developed formulations had small uniform particle sizes and were stable for three months. Nanonization caused decreased crystallite size and induced crystal defects formation, as well as a DK-I-60-3 solubility increase. Furthermore, after oral administration of the developed formulations in rats, two to three-fold bioavailability enhancement was observed in plasma and investigated organs, including the brain.
format Online
Article
Text
id pubmed-8400889
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84008892021-08-29 Overcoming the Low Oral Bioavailability of Deuterated Pyrazoloquinolinone Ligand DK-I-60-3 by Nanonization: A Knowledge-Based Approach Mitrović, Jelena R. Divović-Matović, Branka Knutson, Daniel E. Đoković, Jelena B. Kremenović, Aleksandar Dobričić, Vladimir D. Randjelović, Danijela V. Pantelić, Ivana Cook, James M. Savić, Miroslav M. Savić, Snežana D. Pharmaceutics Article Poor water solubility of new chemical entities is considered as one of the main obstacles in drug development, as it usually leads to low bioavailability after administration. To overcome these problems, the selection of the appropriate formulation technology needs to be based on the physicochemical properties of the drug and introduced in the early stages of drug research. One example of the new potential drug substance with poor solubility is DK-I-60-3, deuterated pyrazoloquinolinone, designed for the treatment of various neuropsychiatric disorders. In this research, based on preformulation studies, nanocrystal technology was chosen to improve the oral bioavailability of DK-I-60-3. Nanocrystal dispersions stabilized by sodium lauryl sulfate and polyvinylpyrrolidone were prepared by modified wet media milling technique, with the selection of appropriate process and formulation parameters. The nanoparticles characterization included particle size and zeta potential measurements, differential scanning calorimetry, X-ray powder diffraction, dissolution and solubility study, and in vivo pharmacokinetic experiments. Developed formulations had small uniform particle sizes and were stable for three months. Nanonization caused decreased crystallite size and induced crystal defects formation, as well as a DK-I-60-3 solubility increase. Furthermore, after oral administration of the developed formulations in rats, two to three-fold bioavailability enhancement was observed in plasma and investigated organs, including the brain. MDPI 2021-07-31 /pmc/articles/PMC8400889/ /pubmed/34452149 http://dx.doi.org/10.3390/pharmaceutics13081188 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mitrović, Jelena R.
Divović-Matović, Branka
Knutson, Daniel E.
Đoković, Jelena B.
Kremenović, Aleksandar
Dobričić, Vladimir D.
Randjelović, Danijela V.
Pantelić, Ivana
Cook, James M.
Savić, Miroslav M.
Savić, Snežana D.
Overcoming the Low Oral Bioavailability of Deuterated Pyrazoloquinolinone Ligand DK-I-60-3 by Nanonization: A Knowledge-Based Approach
title Overcoming the Low Oral Bioavailability of Deuterated Pyrazoloquinolinone Ligand DK-I-60-3 by Nanonization: A Knowledge-Based Approach
title_full Overcoming the Low Oral Bioavailability of Deuterated Pyrazoloquinolinone Ligand DK-I-60-3 by Nanonization: A Knowledge-Based Approach
title_fullStr Overcoming the Low Oral Bioavailability of Deuterated Pyrazoloquinolinone Ligand DK-I-60-3 by Nanonization: A Knowledge-Based Approach
title_full_unstemmed Overcoming the Low Oral Bioavailability of Deuterated Pyrazoloquinolinone Ligand DK-I-60-3 by Nanonization: A Knowledge-Based Approach
title_short Overcoming the Low Oral Bioavailability of Deuterated Pyrazoloquinolinone Ligand DK-I-60-3 by Nanonization: A Knowledge-Based Approach
title_sort overcoming the low oral bioavailability of deuterated pyrazoloquinolinone ligand dk-i-60-3 by nanonization: a knowledge-based approach
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400889/
https://www.ncbi.nlm.nih.gov/pubmed/34452149
http://dx.doi.org/10.3390/pharmaceutics13081188
work_keys_str_mv AT mitrovicjelenar overcomingtheloworalbioavailabilityofdeuteratedpyrazoloquinolinoneliganddki603bynanonizationaknowledgebasedapproach
AT divovicmatovicbranka overcomingtheloworalbioavailabilityofdeuteratedpyrazoloquinolinoneliganddki603bynanonizationaknowledgebasedapproach
AT knutsondaniele overcomingtheloworalbioavailabilityofdeuteratedpyrazoloquinolinoneliganddki603bynanonizationaknowledgebasedapproach
AT đokovicjelenab overcomingtheloworalbioavailabilityofdeuteratedpyrazoloquinolinoneliganddki603bynanonizationaknowledgebasedapproach
AT kremenovicaleksandar overcomingtheloworalbioavailabilityofdeuteratedpyrazoloquinolinoneliganddki603bynanonizationaknowledgebasedapproach
AT dobricicvladimird overcomingtheloworalbioavailabilityofdeuteratedpyrazoloquinolinoneliganddki603bynanonizationaknowledgebasedapproach
AT randjelovicdanijelav overcomingtheloworalbioavailabilityofdeuteratedpyrazoloquinolinoneliganddki603bynanonizationaknowledgebasedapproach
AT pantelicivana overcomingtheloworalbioavailabilityofdeuteratedpyrazoloquinolinoneliganddki603bynanonizationaknowledgebasedapproach
AT cookjamesm overcomingtheloworalbioavailabilityofdeuteratedpyrazoloquinolinoneliganddki603bynanonizationaknowledgebasedapproach
AT savicmiroslavm overcomingtheloworalbioavailabilityofdeuteratedpyrazoloquinolinoneliganddki603bynanonizationaknowledgebasedapproach
AT savicsnezanad overcomingtheloworalbioavailabilityofdeuteratedpyrazoloquinolinoneliganddki603bynanonizationaknowledgebasedapproach